The Imaging Genetic Study of Type 2 Diabetes and Depression
The Study of Structural and Functional Brain Abnormalities and the Association With the Genetic Polymorphism in the Type 2 Diabetes Patient With Depression
1 other identifier
observational
120
1 country
1
Brief Summary
To investigate the structural/functional abnormalities and the possible genetic endophenotypes of in the Type 2 Diabetes Patient With Depression.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Dec 2017
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2017
CompletedFirst Submitted
Initial submission to the registry
June 11, 2018
CompletedFirst Posted
Study publicly available on registry
June 20, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2020
CompletedSeptember 17, 2019
September 1, 2019
3 years
June 11, 2018
September 15, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
the neuroimaging of Type 2 Diabetes and Depression
the structure and function of Abnormalities in the T2DM Patients
from 2017-12 to 2019-12
Study Arms (4)
controls
T2DM patients
depression patients
T2DM with depression patients
Interventions
magnetic resonance spectrum of brain
Eligibility Criteria
T2DM and depression patients
You may qualify if:
- conform to type 2 diabetes, depression, diagnostic criteria of unrelated normal controls the han nationality patients; Aged 30 to 70 years of age, gender not limited; The patient or legal guardian have signed informed consent of patients.
You may not qualify if:
- Magnetic resonance imaging has the contraindication, such as metal implants, claustrophobic, etc.
- With severe body diseases, including inflammatory diseases and autoimmune diseases; Current or past history of nervous system disease or brain injury. Merge other severe mental illness or existing psychotic symptoms; Always have a mania, hypomania attack; Has a history of substance abuse; Pregnant women and nursing mothers; Estimated compliance is poorer, not partners; Is being treated for a mental drug therapy, and ECT, TMS; Patients with a body mass index \> 35; There are currently no taking corticosteroids, immune regulator, etc. Now or ever did not suffer from patients with other diagnosis to the dsm-iv axis I; Merge the endocrine system disease, thyroid, adrenal gland and pituitary gland diseases, etc.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Psychiatry department, The 1st Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, 650032, China
Related Publications (1)
Cui F, Ouyang ZQ, Zeng YZ, Ling BB, Shi L, Zhu Y, Gu HY, Jiang WL, Zhou T, Sun XJ, Han D, Lu Y. Effects of hypertension on subcortical nucleus morphological alternations in patients with type 2 diabetes. Front Endocrinol (Lausanne). 2023 Sep 13;14:1201281. doi: 10.3389/fendo.2023.1201281. eCollection 2023.
PMID: 37780620DERIVED
Biospecimen
perapheral blood DNA of all participants
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Xiufeng Xu, MD
Psychiatry department of KMU
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- associate professor
Study Record Dates
First Submitted
June 11, 2018
First Posted
June 20, 2018
Study Start
December 1, 2017
Primary Completion
December 1, 2020
Study Completion
December 1, 2020
Last Updated
September 17, 2019
Record last verified: 2019-09
Data Sharing
- IPD Sharing
- Will not share